Evidence map›Paper›PMID 38438797›Full record

ArticleEye (London, England)2024

Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs.

Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Francesco Bandello, Anat Loewenstein, Baruch D Kuppermann

Abstract readLetter
In one paragraph

Article in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Peep into anti-vascular endothelial growth factor.Indian journal of ophthalmology · 2026
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ashish SharmaLotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India. drashish79@hotmail.com.ORCID http://orcid.org/0000-0002-8550-9791
Nilesh KumarMadhavi Netralaya, Ara, Bihar, India.ORCID http://orcid.org/0000-0002-7439-2081
Nikulaa ParachuriSankara eye Hospital, Coimbatore, TN, India.
Francesco BandelloUniversity Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.ORCID http://orcid.org/0000-0003-3238-9682
Anat LoewensteinDivision of Ophthalmology, Tel Aviv Medical University, Tel Aviv, Israel.ORCID http://orcid.org/0000-0002-7706-1165
Baruch D KuppermannGavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Angiogenesis InhibitorsBiosimilar PharmaceuticalsRanibizumabClinical Trials, Phase III as TopicHumansIndiaIntravitreal InjectionsResearch DesignVascular Endothelial Growth Factor AAngiogenesis InhibitorsBiosimilar PharmaceuticalsRanibizumabVascular Endothelial Growth Factor A

Identifiers

PMID38438797
PMCPMC11226708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.